Median OS was @ months for figitumumab plus chemotherapy and @ months for chemotherapy alone ( hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @ to @ ; P = @ ) ; median progression-free survival was @ months ( @ % CI , @ to @ ) and @ months ( @ % CI , @ to @ ) , respectively ( HR , @ ; P = @ ) ; the objective response rates were @ % and @ % , respectively .